Abstract 298P
Background
It was still controversial regarding the postoperative preservation of pulmonary function after segmentectomy over lobectomy. In particular, resection for three or more segment was associated with more profound decreased in lung function. The purpose of this study was to investigate the effect of left upper division (LUD) segmentectomy on postoperative pulmonary function and lung volume comparison of left upper lobectomy among clinical stage IA non-small cell lung cancer (NSCLC).
Methods
Among clinical stage IA NSCLC patients who underwent LUD segmentectomy or left upper lobectomy between 2013 and 2018, postoperative changes in pulmonary function, 3-dimensional computed tomography (CT) volumetry and the percentage of low attenuation areas (% LAAs) were retrospectively reviewed according to surgical procedure. Changes in pulmonary function by groups were compared using linear mixed model with linear spline, random intercepts and slope.
Results
A total of 264 patient were identified, the study group consisted with 85 LUD segmentectomy (32.2%) and 179 left lobectomy (67.8%). In the adjusted model, no significant difference was observed among changes in pulmonary function by surgical procedure. In terms of lung volume, postoperative volume in contralateral lung and LLL was increased in both groups, it is more likely to have greater increase in LLL volume in lobectomy group (333.4 vs. 451.6 ml, p<0.001) than those in segmentectomy group. After surgery, the % LAA of left lung and LLL in the lobectomy group significantly increased compared to those in the segmentectomy group (0.37 vs. 1.31, p=0.002; 0.53 vs. 1.82, p<0.001), while change of % LAA of right lung was not significantly differ by surgical procedure. In the linear regression model, changes in lung volume and % LAA in left lung and LLL was significantly associated with type of surgery.
Conclusions
Postoperative changes in pulmonary function after LUD segmentectomy and left upper lobectomy was not significantly different. However, segmentectomy was significantly associated with less volume expansion and less increased % LAA compared with those in lobectomy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
303P - Long-term oncologic outcomes for patients undergoing volatile versus intravenous anesthesia for non-small cell lung cancer surgery
Presenter: Ji Hyung Hong
Session: Poster viewing 04
306P - Multimodal management and outcomes of stage III non-small cell lung cancer: KINDLE-Egypt analysis
Presenter: Rasha Aboelhassan
Session: Poster viewing 04
307P - Differential expression profiling of transcripts in stage IIIA non-small cell lung cancer (NSCLC) of smokers and non-smokers cases of north India: A geneto-environmental study
Presenter: Archana Mishra
Session: Poster viewing 04
308P - Phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
Presenter: Masanao Nakashima
Session: Poster viewing 04
309P - Pneumonitis and corticosteroid treatment in patients with unresectable non-small cell lung cancer receiving durvalumab consolidation after definitive chemoradiotherapy
Presenter: Saori Murata
Session: Poster viewing 04
311P - Cost-effectiveness of alectinib compared with chemotherapy in first-line treatment for anaplastic lymphoma kinase-positive (ALK+) advanced non-small cell lung cancer in Thailand
Presenter: Sermsiri Sangroongruangsri
Session: Poster viewing 04
312P - ClinMatch: A clinical trial matching platform that improves trial accessibility among NSCLC patients through comprehensive genomic and clinical profiling
Presenter: Allen Chi Shing Yu
Session: Poster viewing 04
313P - A pool analysis of MET TKI SCC244 in NSCLC patients with MET overexpression
Presenter: Yongfeng Yu
Session: Poster viewing 04